Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV-F Vaccine in Healthy Elderly Subjects
NCT02266628Phase 2Completed
- Sponsor
- Novavax
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RSV F vaccine + aluminum phosphate in respiratory syncytial virus infection (RSV), sponsored by Novavax. Started Oct 2014; status: completed.
02
Drugs
RSV F vaccine + aluminum phosphate
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02266628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266628.